Merck & Co Inc. (MRK) Monday announced positive topline results from the Phase 3 HYPERION study evaluating Winrevair in adults with recently diagnosed pulmonary arterial hypertension (PAH). The study met its primary goal.
The HYPERION study is designed to evaluate Winrevair when added to background PAH therapy versus placebo in newly diagnosed intermediate or high-risk PAH patients. The primary endpoint of the study was time to clinical worsening (TTCW), the need for non-planned PAH-related hospitalization for more than 24 hours, atrial septostomy, lung transplantation, or PAH deterioration.
Winrevair is alredy approved by the FDA for the treatment of adults with PAH to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.